Key result
Among patients with chronic atrial fibrillation, 42% received no thromboembolism prophylaxis, while 34% received anticoagulation and 22% received antiplatelet agents.
Why the study?
What are the practice patterns and clinical factors influencing the use of thromboembolism prophylaxis in patients with chronic atrial fibrillation?
Observational (n=651)
Yes
What are the practice patterns and clinical factors influencing the use of thromboembolism prophylaxis in patients with chronic atrial fibrillation?
Absolute Event Rate: 56% vs 42%
Thromboembolism prophylaxis is significantly underutilized in patients with chronic atrial fibrillation, particularly among older patients and those treated in community hospitals.
No takes yet. Share an insight, caveat, or question.
Indicates underutilization of prophylaxis in chronic AF; leaves open questions on barriers in older patients and community hospitals.
Munschauer et al. (1997) conducted an observational in Chronic Atrial Fibrillation (n=651). Anticoagulation or antiplatelet agents vs. No specific antiembolic therapy was evaluated on Use of thromboembolism prophylaxis. Among patients with chronic atrial fibrillation, 42% received no thromboembolism prophylaxis, while 34% received anticoagulation and 22% received antiplatelet agents.